Investor Relations > details

rhNRG-1 Obtained SFDA Approval for Phase III Clinical Trial


rhNRG-1 was approved by SFDA to take phase III clinical trial (2010L00444). Based on the progress of previous clinical trials of rhNRG-1, Zensun expected to finish clinical study, new drug application (NDA) and manufacturing approval in two years. Zensun hope that rhNRG-1 could make breakthrough in heart failure drug development and provide benefit of the many millions of heart failure sufferers world-wide.